心力衰竭
医学
线粒体
粒线体疾病
疾病
生物信息学
预期寿命
氧化磷酸化
线粒体DNA
活性氧
线粒体ROS
氧化应激
重症监护医学
生物
内科学
细胞生物学
环境卫生
遗传学
生物化学
人口
基因
作者
Chennan Wu,Zhen Zhang,Weidong Zhang,Xia Liu
标识
DOI:10.1016/j.phrs.2021.106038
摘要
Cardiovascular diseases remain the leading cause of death worldwide in the last decade, accompanied by immense health and economic burdens. Heart failure (HF), as the terminal stage of many cardiovascular diseases, is a common, intractable, and costly medical condition. Despite significant improvements in pharmacologic and device therapies over the years, life expectancy for this disease remains poor. Current therapies have not reversed the trends in morbidity and mortality as expected. Thus, there is an urgent need for novel potential therapeutic agents. Although the pathophysiology of the failing heart is extraordinarily complex, targeting mitochondrial dysfunction can be an effective approach for potential treatment. Increasing evidence has shown that mitochondrial abnormalities, including altered metabolic substrate utilization, impaired mitochondrial oxidative phosphorylation (OXPHOS), increased reactive oxygen species (ROS) formation, and aberrant mitochondrial dynamics, are closely related to HF. Here, we reviewed the findings on the role of mitochondrial dysfunction in HF, along with novel mitochondrial therapeutics and their pharmacological effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI